Drugs / Amphetamine-Dextroamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03772314 | Apr 2019 → May 2023 | idiopathic hypersomnia, narcolepsy without cataplexy | Emory University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05597722 Comparator | Apr → May 2023 | cognitive disorder, long COVID-19 | Eva Szigethy | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amphetamine-Dextroamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05597722 ↗ |
| Known as | amphetamine salts | “Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).” NCT03772314 ↗ |
| Route | Oral | “Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.” NCT03772314 ↗ |